ICH Score

The Intracerebral Hemorrhage (ICH) Score is a critical clinical-operational metric used to risk-stratify patients presenting with spontaneous intracranial bleeding. Originally developed in 2001 at the University of California San Francisco, this validated scoring system serves as a cornerstone for predicting 30-day mortality. For healthcare executives, clinical operations managers, and medical directors, the score is not merely a prognostic tool; it is an essential instrument for ICU bed allocation, staffing optimization, and clinical pathway standardization. By categorizing patients based on neurological status, hematoma volume, anatomical location, and demographic risk, healthcare systems can deploy specialized neurocritical care resources where they will yield the highest clinical and financial return. From a financial and risk-management perspective, the ICH Score is invaluable for value-based care organizations, commercial insurers, and hospital CFOs. Spontaneous ICH cases represent some of the most resource-intensive admissions in the healthcare sector, often resulting in prolonged ICU stays, mechanical ventilation, and complex surgical interventions. Utilizing this structured risk-grading system allows actuarial analysts and case managers to project length of stay (LOS), anticipate post-acute care needs, and establish accurate financial reserves. It also prevents the misallocation of high-cost interventions in cases where palliative or comfort-focused pathways are clinically indicated and aligned with patient goals. Furthermore, the ICH Score plays a pivotal role in clinical trial design and pharmaceutical research and development. Biotech companies and clinical research organizations (CROs) utilize the score to stratify patient cohorts, ensuring that treatment and control arms are balanced for baseline stroke severity. This rigorous stratification controls for confounding variables, reduces the statistical noise that can derail expensive Phase III trials, and ultimately accelerates the time-to-market for novel neuroprotective therapies and surgical devices.

Calkulon makes complex calculations simple — built for students and everyday problem-solvers.

1. 1Assess the Glasgow Coma Scale (GCS) score upon patient admission: assign 2 points for severe impairment (GCS 3-4), 1 point for moderate impairment (GCS 5-12), and 0 points for mild or absent impairment (GCS 13-15).
2. 2Calculate the volume of the parenchymal hemorrhage using the ABC/2 method on a non-contrast CT scan; assign 1 point if the volume is 30 mL or greater, and 0 points if it is under 30 mL.
3. 3Determine the presence of intraventricular hemorrhage (IVH) via neuroimaging, assigning 1 point if blood has entered the ventricular system and 0 points if it has not.
4. 4Identify the anatomical origin of the bleed: assign 1 point for an infratentorial origin (brainstem or cerebellum) and 0 points for a supratentorial location.
5. 5Verify the patient's age from their medical record, assigning 1 point if the patient is 80 years of age or older, and 0 points if they are under 80.
6. 6Aggregate the points from all five categories to generate a final ICH Score ranging from 0 to 6.
7. 7Cross-reference the final score with validated 30-day mortality risk percentages to guide clinical resource allocation, financial forecasting, and family counseling.

• !Prematurely limiting active therapeutic interventions or writing DNR orders based solely on a high admission ICH Score, which artificially drives up mortality rates through a self-fulfilling prophecy.
• !Applying the ABC/2 volume calculation incorrectly by using the hematoma's radius instead of its diameter, resulting in a severe underestimation of the bleed volume.
• !Utilizing the ICH Score for patients with traumatic brain injuries (TBI) or hemorrhagic transformations of ischemic strokes, populations for whom this specific clinical prediction rule has not been validated.